ReviewDrugs in R&D2017

Vorapaxar: The Current Role and Future Directions of a Novel Protease-Activated Receptor Antagonist for Risk Reduction in Atherosclerotic Disease.

Rebecca J Gryka et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.